WO2023231730A3 - 使用mazdutide的治疗方法 - Google Patents

使用mazdutide的治疗方法 Download PDF

Info

Publication number
WO2023231730A3
WO2023231730A3 PCT/CN2023/093311 CN2023093311W WO2023231730A3 WO 2023231730 A3 WO2023231730 A3 WO 2023231730A3 CN 2023093311 W CN2023093311 W CN 2023093311W WO 2023231730 A3 WO2023231730 A3 WO 2023231730A3
Authority
WO
WIPO (PCT)
Prior art keywords
need
mazdutide
target compound
present
prophylactically
Prior art date
Application number
PCT/CN2023/093311
Other languages
English (en)
French (fr)
Other versions
WO2023231730A2 (zh
Inventor
蔡成行
刘蒙
邓焕
宋柏力
文洁
Original Assignee
信达生物制药(苏州)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 信达生物制药(苏州)有限公司 filed Critical 信达生物制药(苏州)有限公司
Publication of WO2023231730A2 publication Critical patent/WO2023231730A2/zh
Publication of WO2023231730A3 publication Critical patent/WO2023231730A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明属于医药领域，具体涉及使用mazdutide的治疗方法。本发明提供了一种用于预防或治疗肥胖或超重的方法，以及一种在有需要的患者中改善体重的方法，上述方法包括在由至少3个给药周期组成的给药方案中向有需要的患者施用预防或治疗有效量的目标化合物。本发明还提供一种目标化合物，其用于在有需要的患者中预防或治疗肥胖或超重，其中，在至少3个给药周期中向有需要的患者施用预防或治疗有效量的所述目标化合物。本发明提供的mazdutide给药方案减重效果非常突出，可以通过较低剂量在较短的时间内达到明显的减重效果，并可同时改善受试者的血压、血脂和血清尿酸水平。
PCT/CN2023/093311 2022-06-01 2023-05-10 使用mazdutide的治疗方法 WO2023231730A2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210622648 2022-06-01
CN202210622648.7 2022-06-01

Publications (2)

Publication Number Publication Date
WO2023231730A2 WO2023231730A2 (zh) 2023-12-07
WO2023231730A3 true WO2023231730A3 (zh) 2024-01-25

Family

ID=89026916

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/093311 WO2023231730A2 (zh) 2022-06-01 2023-05-10 使用mazdutide的治疗方法

Country Status (1)

Country Link
WO (1) WO2023231730A2 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735100A (zh) * 2015-06-22 2018-02-23 伊莱利利公司 胰高血糖素和glp‑1协同激动剂化合物
CN109745547A (zh) * 2017-11-06 2019-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双激动剂多肽治疗胆汁性肝硬化
CN111423506A (zh) * 2019-11-08 2020-07-17 成都奥达生物科技有限公司 一种glp-1化合物
WO2022268174A1 (zh) * 2021-06-25 2022-12-29 信达生物制药(苏州)有限公司 Mazdutide的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735100A (zh) * 2015-06-22 2018-02-23 伊莱利利公司 胰高血糖素和glp‑1协同激动剂化合物
CN109745547A (zh) * 2017-11-06 2019-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双激动剂多肽治疗胆汁性肝硬化
CN111423506A (zh) * 2019-11-08 2020-07-17 成都奥达生物科技有限公司 一种glp-1化合物
WO2022268174A1 (zh) * 2021-06-25 2022-12-29 信达生物制药(苏州)有限公司 Mazdutide的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JI LINONG, GAO LEILI, JIANG HONGWEI, YANG JING, YU LEI, WEN JIE, CAI CHENGHANG, DENG HUAN, FENG LIQI, SONG BAILI, MA QINGYANG, QIA: "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial", ECLINICAL MEDICINE, vol. 54, 1 December 2022 (2022-12-01), pages 101691, XP093132130, ISSN: 2589-5370, DOI: 10.1016/j.eclinm.2022.101691 *
JIANG HONGWEI, PANG SHUGUANG, ZHANG YAWEI, YU TING, LIU MENG, DENG HUAN, LI LI, FENG LIQI, SONG BAILI, HAN-ZHANG HAN, MA QINGYANG,: "A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 13, no. 1, 24 June 2022 (2022-06-24), UK, pages 3613, XP093132131, ISSN: 2041-1723, DOI: 10.1038/s41467-022-31328-x *

Also Published As

Publication number Publication date
WO2023231730A2 (zh) 2023-12-07

Similar Documents

Publication Publication Date Title
EP1744739B1 (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
EP1696932B1 (en) Use of treprostinil to improve kidney functions
JP2022009125A5 (zh)
Krasagakis et al. Management of severe scleroderma with long-term extracorporeal photopheresis
KR20060123483A (ko) 허혈성 병변의 치료 및 예방을 위한 트레프로스티닐의 용도
JP3721196B2 (ja) 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用
EP1369119B1 (en) Il-12 expression controlling agents
WO2016173486A1 (zh) 曲美他嗪在制备防治肝病的药物中的用途
WO2022039619A1 (ru) Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2)
EP0630649A1 (en) Combination of an inhibitor of inducible nitric oxide synthase (iNOS) and an antiinflammatory agent, e.g. a corticosteroid
Ng et al. Phycomycotic abscesses in a preterm infant.
WO2023231730A3 (zh) 使用mazdutide的治疗方法
Logunova et al. Antihypertensive effectiveness and tolerability of perindopril/indapamide/amlodipine triple single‐pill combination in the treatment of patients with arterial hypertension (TRICOLOR)
RU2745986C1 (ru) Противокоронавирусное средство для комбинированной терапии COVID-19 (SARS-CoV-2) и способ лечения
CN1299676C (zh) 一种抗缺氧药物组合物
US6355682B1 (en) Treatment of acute renal failure by administration of N-acetylcysteine
RU2370264C2 (ru) Способ детоксикации организма в хирургии местнораспространенного гипернефроидного рака
RU2585097C1 (ru) Способ лечения хронического панкреатита
Kawano et al. Successful treatment of heart failure in an adult patient with Prader-Willi syndrome
RU2746161C1 (ru) Фармацевтический набор для комбинированной терапии COVID-19 (SARS-CoV-2) и способ его применения
SU1194418A1 (ru) Способ лечени детей с острой гнойной деструктивной пневмонией
Gudieva et al. EFFECTS OF FIXED DOSE COMBINATION AZILSARTAN MEDOXOMIL/CHLORTALIDONE ON THE CENTRAL BP IN HYPERTENSIVE PATIENTS WITH HFPEF
RU2071773C1 (ru) Лекарственное средство для лечения синдромов приобретенного иммунодефицита, в том числе вич-обусловленных
Chung et al. CILNIDIPINE DECREASES LEFT ATRIAL VOLUME INDEX SUPERIOR THAN ATENOLOL IN THE PATIENTS WITH HYPERTENSION
DuBose et al. Thermal Burns, Electrical Burns, Chemical Burns, Inhalational Injury, and Lightning Injuries

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23814915

Country of ref document: EP

Kind code of ref document: A2